Background: Nonsense mutations in FAM83H are a recently described underlying cause of autosomal dominant (AD) hypocalcified amelogenesis imperfecta (AI). Objective: This study aims to report a novel c.1374C>A p.Y458X nonsense mutation and describe the associated ultrastructural phenotype of deciduous teeth. Methods: A family of European origin from the Iberian Peninsula with AD-inherited AI was ascertained. Family members were assessed through clinical examination and supporting investigations. Naturally exfoliated deciduous teeth from 2 siblings were investigated by scanning electron microscopy (SEM), energy dispersive X-ray analysis (EDX) and transverse microradiography (TMR). Results: On clinical and radiographic investigation the appearances of the affected deciduous and permanent teeth were consistent with hypocalcified AI with small focal areas of more normal looking enamel. DNA sequencing identified a novel c.1374C>A p.Y458X FAM83H nonsense mutation in affected, but not in either unaffected family members or unrelated controls. Exfoliated teeth were characterised by substantial post-eruptive enamel loss on gross examination. Irregular, poor quality enamel prisms were observed on SEM. These were coated in amorphous material. TMR and EDX confirmed reduced mineral and increased organic content in enamel, respectively. Conclusions: FAM83H nonsense mutations have recently been recognised as a cause of AD hypocalcified AI. We report a novel nonsense FAM83H mutation and describe the associated preliminary ultrastructural phenotype in deciduous teeth. This is characterised by poorly formed enamel rods with inappropriate retention of amorphous material, which is likely to represent retained organic matrix that contributes to the overall hypomineralised phenotype.

Keywords:
Amelogenesis imperfecta, FAM83H, Enamel, Deciduous teeth, Scanning electron microscopy
1.
Aldred, M.J., R. Savarirayan, P.J. Crawford (2003) Amelogenesis imperfecta: a classification and catalogue for the 21st century. Oral Dis 9: 19–23.
2.
Barron, M.J., S.J. Brookes, C.E. Draper, D. Garrod, J. Kirkham, R.C. Shore, M.J. Dixon (2008) The cell adhesion molecule nectin-1 is critical for normal enamel formation in mice. Hum Mol Genet 17: 3509–3520.
3.
Cuisinier, F.J., P. Steuer, B. Senger, J.C. Voegel, R.M. Frank (1992) Human amelogenesis. I: High resolution electron microscopy study of ribbon-like crystals. Calcif Tissue Int 51: 259–268.
4.
Hart, P.S., S. Becerik, D. Cogulu, G. Emingil, D. Ozdemir-Ozenen, S.T. Han, P.P. Sulima, E. Firatli, T.C. Hart (2009) Novel FAM83H mutations in Turkish families with autosomal dominant hypocalcified amelogenesis imperfecta. Clin Genet 75: 401–404.
5.
Hart, P.S., T.C. Hart, M.D. Michalec, O.H. Ryu, D. Simmons, S. Hong, J.T. Wright (2004) Mutation in kallikrein 4 causes autosomal recessive hypomaturation amelogenesis imperfecta. J Med Genet 41: 545–549.
6.
Kim, J.W., S.K. Lee, Z.H. Lee, J.C. Park, K.E. Lee, M.H. Lee, J.T. Park, B.M. Seo, J.C. Hu, J.P. Simmer (2008) FAM83H mutations in families with autosomal-dominant hypocalcified amelogenesis imperfecta. Am J Hum Genet 82: 489–494.
7.
Kim, J.W., J.P. Simmer, T.C. Hart, P.S. Hart, M.D. Ramaswami, J.D. Bartlett, J.C. Hu (2005) MMP-20 mutation in autosomal recessive pigmented hypomaturation amelogenesis imperfecta. J Med Genet 42: 271–275.
8.
Kirkham, J., C. Robinson, J.A. Weatherell, A. Richards, O. Fejerskov, K. Josephsen (1988) Maturation in developing permanent porcine enamel. J Dent Res 67: 1156–1160.
9.
Lee, S.K., J.C. Hu, J.D. Bartlett, K.E. Lee, B.P. Lin, J.P. Simmer, J.W. Kim (2008) Mutational spectrum of FAM83H: the C-terminal portion is required for tooth enamel calcification. Hum Mutat 29: E95–E99.
10.
Lu, Y., P. Papagerakis, Y. Yamakoshi, J.C. Hu, J.D. Bartlett, J.P. Simmer (2008) Functions of KLK4 and MMP-20 in dental enamel formation. Biol Chem 389: 695–700.
11.
Nanci, A., C.E. Smith (1992) Development and calcification of enamel; in: Mineralization in Biological Systems. Boca Raton, CRC Press, pp 313–343.
12.
Parry, D.A., A.J. Mighell, W. El-Sayed, R.C. Shore, I.K. Jalili, H. Dollfus, A. Bloch-Zupan, R. Carlos, I.M. Carr, L.M. Downey, K.M. Blain, D.C. Mansfield, M. Shahrabi, M. Heidari, P. Aref, M. Abbasi, M. Michaelides, A.T. Moore, J. Kirkham, C.F. Inglehearn (2009) Mutations in CNNM4 cause Jalili syndrome, consisting of autosomal-recessive cone-rod dystrophy and amelogenesis imperfecta. Am J Hum Genet 84: 266–273.
13.
Robinson, C., J. Kirkham, J.A. Weatherell, A. Richards, K. Josephsen, O. Fejerskov (1988) Mineral and protein concentrations in enamel of the developing permanent porcine dentition. Caries Res 22: 321–326.
14.
Shore, R.C., B. Backman, S.J. Brookes, J. Kirkham, S.R. Wood, C. Robinson (2002) Inheritance pattern and elemental composition of enamel affected by hypomaturation amelogenesis imperfecta. Connect Tissue Res 43: 466–471.
15.
Smith, C.E., W.Y. Chen, M. Issid, A. Fazel (1995) Enamel matrix protein turnover during amelogenesis: basic biochemical properties of short-lived sulfated enamel proteins. Calc Tissue Int 57: 133–144.
16.
Warshawsky, H., C.E. Smith (1974) Morphological classification of rat incisor ameloblasts. Anat Rec 179: 423–446.
17.
Witkop, C.J. Jr (1988) Amelogenesis imperfecta, dentinogenesis imperfecta and dentin dysplasia revisited: problems in classification. J Oral Pathol 17: 547–553.
18.
Wright, J.T., V. Lord, C. Robinson, R. Shore (1992) Enamel ultrastructure in pigmented hypomaturation amelogenesis imperfecta. J Oral Pathol Med 21: 390–394.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.